Share chart Kodiak Sciences Inc.
Extended chart
Simple chart
About
Kodiak Sciences Inc., биофармацевтическая компания, работающая на клинической стадии, предлагает новые терапевтические препараты для лечения заболеваний сетчатки. Ведущим кандидатом на продукт компании является KSI-301, биологический агент фактора роста эндотелия сосудов (VEGF), который находится в фазе 1b клинического исследования для лечения влажной возрастной дегенерации желтого пятна (AMD) и диабетической ретинопатии. more details| IPO date | 2018-10-04 |
|---|---|
| ISIN | US50015M1099 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Див.доход ао | 0 |
| Сайт | http://kodiak.com |
| Цена ао | 8.32 |
| Change price per day: | 0% (8.32) |
|---|---|
| Change price per week: | -10.73% (9.32) |
| Change price per month: | -0.5974% (8.37) |
| Change price per 3 month: | +187.89% (2.89) |
| Change price per half year: | +176.41% (3.01) |
| Change price per year: | +152.12% (3.3) |
| Change price per 3 year: | -85.83% (58.7) |
| Change price per 5 year: | -87.41% (66.06) |
| Change price per 10 year: | 0% (8.32) |
| Change price per year to date: | -4.15% (8.68) |
|
|
Underestimation
|
Efficiency
|
|||||||||||||||||||||||||||||||||||||
Dividends
|
Debt
|
Growth impulse
|
|||||||||||||||||||||||||||||||||||||
| Institutions | Volume | Share, % |
|---|---|---|
| Baker Brothers Advisors, LLC | 17310490 | 32.97 |
| Blackrock Inc. | 4032822 | 7.68 |
| Acadian Asset Management. LLC | 1908302 | 3.63 |
| Newtyn Management, LLC | 1771241 | 3.37 |
| Vanguard Group Inc | 1643470 | 3.13 |
| Shaw D.E. & Co., Inc. | 1208973 | 2.3 |
| ICONIQ Capital, LLC | 1016864 | 1.94 |
| SILVERARC CAPITAL MANAGEMENT, LLC | 1000000 | 1.9 |
| Jacobs Levy Equity Management, Inc. | 723675 | 1.38 |
| State Street Corporation | 720435 | 1.37 |
| ETF | Share, % | Profitability for 1 year, % | Dividends, % |
|---|---|---|---|
| ProShares UltraShort Nasdaq Biotechnology | 0.35 | -40.36 | 1.76 |
| iShares Micro-Cap ETF | 0.02184 | 17.09 | 1.54048 |
| Avantis U.S Small Cap Equity ETF | 0.01021 | 27.77 | 1.68271 |
| Invesco FTSE RAFI US 1500 Small-Mid ETF | 0.00536 | 17.58 | 1.75869 |
| Dimensional U.S. Targeted Value ETF | 0.00235 | 26.01 | 1.93487 |
Schwab U.S. Small-Cap ETF
|
0.00234 | 17.47 | 1.51433 |
ProShares UltraPro Russell2000
|
0.00186 | 89.82 | 1.47873 |
| ProShares Hedge Replication ETF | 0.00053 | 5.92 | 1.47892 |
| iShares Russell 3000 ETF | 0.00025 | 24.83 | 1.43482 |
Schwab U.S. Broad Market ETF
|
0.00018 | 24.86 | 1.43354 |
| Avantis U.S. Equity ETF | 0.00012 | 23.04 | 1.59151 |
| Dimensional US Core Equity Market ETF | 0.00007 | 30.98 | 1.40618 |
| Dimensional U.S. Equity ETF | 0.00006 | 31.53 | 1.3557 |
| Vanguard Russell 2000 ETF | 0 | 17.16 | 1.48801 |
| Vanguard Russell 3000 ETF | 0 | 31.87 | 1.43817 |
| Head | Job title | Payment | Year of birth |
|---|---|---|---|
| Ms. Almas Qudrat M.Sc. | Chief Quality Officer | N/A | |
| Dr. Victor Perlroth M.D. | Co-Founder, Chairman, CEO & President | 1.08M | 1973 (52 years) |
| Dr. Stephen Raillard Ph.D. | Senior Vice President of Chemical Development & Manufacturing | N/A | |
| Dr. J. Pablo Velazquez-Martin M.D. | Chief Medical Officer | N/A | |
| Mr. John A. Borgeson CPA, M.B.A. | Executive VP, CFO & Secretary | 667.52k | 1963 (62 years) |
| Dr. Dolly S. Chang M.D., M.P.H., Ph.D. | Chief Scientific Officer | ||
| Dr. Hong Liang Ph.D. | Senior Vice President of Development | 1972 (53 years) | |
| Ms. Tracy Chien | VP & Corporate Controller |
Address: United States, Palo Alto, CA , 1200 Page Mill Road - open in Google maps, open in Yandex maps
Website: http://kodiak.com
Website: http://kodiak.com
